Cell Signaling Technology, Inc. Awarded Patents Critical to Lung Cancer Therapy

Published: Jul 09, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) announced today the issuance of a key US patent, 8,481,279, which relates to methods for inhibiting the progression of lung cancers that express the EML4-ALK fusion gene. The ALK fusion gene is an alteration or defect in a normal gene called anaplastic lymphoma kinase (ALK) that is thought to play a critical role in the growth of some non-small cell lung cancers (NSCLCs) and has been central to the development of several promising new, targeted cancer therapeutics.

Help employers find you! Check out all the jobs and post your resume.

Back to news